Strategic partnerships Inivata actively collaborates with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its broader platform, indicating a strong sales path through co-development and commercial partnerships with pharma partners seeking liquid biopsy solutions.

Clinical utility focus The InVisionFirst-Lung platform delivers molecular insights from blood tests to guide NSCLC treatment decisions, suggesting opportunities to target oncologists and health systems prioritizing actionable ctDNA data and personalized therapy planning.

Growth through RaDaR RaDaR assay offerings for residual disease and relapse tracking present a recurring revenue opportunity with hospital labs and cancer centers seeking longitudinal ctDNA monitoring across cancer types.

Clinical trial readiness Inivata’s history of clinical studies and ongoing research presence, including CMO leadership additions, positions the company to partner with CROs and biopharma for companion diagnostics and trial enrichment using ctDNA.

Geographic and lab footprint With a CLIA laboratory in North Carolina and R&D labs in the UK, there are multi-region deployment opportunities and potential for partner labs to integrate Inivata solutions into existing workflows, expanding market reach.